(Q39677540)

English

Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study

scientific article published on May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study (English)

1 reference

Europe PubMed Central

13 September 2017

magnetic resonance imaging

0 references

1 reference

based on heuristic

inferred from title

author name string

Tobias Bäuerle

1

1 reference

Europe PubMed Central

13 September 2017

Dorde Komljenovic

2

1 reference

Europe PubMed Central

13 September 2017

Maximilian Merz

3

1 reference

Europe PubMed Central

13 September 2017

Martin R Berger

4

1 reference

Europe PubMed Central

13 September 2017

Simon L Goodman

5

1 reference

Europe PubMed Central

13 September 2017

Wolfhard Semmler

6

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

1 May 2011

1 reference

Europe PubMed Central

13 September 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

13 September 2017

128

1 reference

Europe PubMed Central

13 September 2017

10

1 reference

Europe PubMed Central

13 September 2017

2453-2462

1 reference

Europe PubMed Central

13 September 2017

Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Integrin signaling revisited

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Integrins: bidirectional, allosteric signaling machines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Alpha-v integrins as therapeutic targets in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Involvement of alpha(v)beta3 integrins in osteoclast function

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

A physical mechanism for coupling bone resorption and formation in adult human bone.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Bone imaging in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Alphavbeta integrins play an essential role in BMP-2 induction of osteoblast differentiation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25563

21 January 2018

Identifiers

10.1002/IJC.25563

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39677540&oldid=1966945564"